COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,442 Articles (22,835 medRxiv, 8,607 bioRxiv)

Most recent first Previous |  Page 914: Articles 9131-9140  | Next

Pegylated-interferon-{lambda} treatment-induced peripheral interferon stimulated genes are associated with SARS-CoV-2 viral load decline despite delayed T cell response in older individuals
Santer, D. M., Li, D., Ghosheh, Y., Zahoor, M. A., Prajapati, D., Tyrrell, D. L. J., Feld, J. J., Gehring, A. J.
10.1101/2022.02.24.22271438 — Posted: 2022-03-03
Z-RNA and the flipside of the SARS Nsp13 helicase
Herbert, A., Shein, A., Poptsova, M.
10.1101/2022.03.03.482810 — Posted: 2022-03-03
Soluble signal inhibitory receptor on leukocytes-1 is released from activated neutrophils by proteinase 3 cleavage
von Richthofen, H. J., Westerlaken, G. H. A., Gollnast, D., Besteman, S., Delemarre, E. M., Rodenburg, K., Moerer, P., Stapels, D. A. C., Andiappan, A. K., Rotzschke, O., Nierkens, S., Leavis, H. L., Bont, L. J., Rooijakkers, S. H. M., Meyaard, L.
10.1101/2022.03.03.482795 — Posted: 2022-03-03
Lack of antiviral activity of probenecid in Vero E6 cells and Syrian golden hamsters: a need for better understanding of inter-lab differences in preclinical assays.
Box, H. J., Pennington, S. H., Kijack, E., Tatham, L., Caygill, C. H., Lopeman, R. C., Jeffreys, L. N., Herriott, J., Sharp, J., Neary, M., Valentijn, A., Pertinez, H., Curley, P., Arshad, U., Rajoli, R. K., Rannard, S., Stewart, J. P., Biagini, G., Owen, A.
10.1101/2022.03.03.482788 — Posted: 2022-03-03
SARS-CoV-2 IgG seroprevalence in the Okinawa Main Island and remote islands in Okinawa, Japan, 2020-2021.
Mizumoto, K., Shimakawa, Y., Aizawa, Y., Butcher, C., Chibana, N., Collins, M., Kameya, K., Kim, T. G., Koyama, S., Matsuyama, R., Matthews, M. M., Mori, T., Nagamoto, T., Narita, M., Omori, R., Shibata, N., Shibata, S., Shiiki, S., Takakura, S., Toyozato, N., Tsuchiya, H., Wolf, M., Yokoyama, S., Yonaha, S., Takayama, Y.
10.1101/2022.03.02.22271759 — Posted: 2022-03-03
Vaccine Breakthrough Infection with the SARS-CoV-2 Delta or Omicron (BA.1) Variant Leads to Distinct Profiles of Neutralizing Antibody Responses
Seaman, M. S., Siedner, M. J., Boucau, J., Lavine, C. L., Ghantous, F., Liew, M. Y., Mathews, J., Singh, A., Marino, C., Regan, J., Uddin, R., Choudhary, M. C., Flynn, J. P., Chen, G., Stuckwisch, A. M., Lipiner, T., Kittilson, A., Melberg, M., Gilbert, R. F., Reynolds, Z., Iyer, S. L., Chamberlin, G. C., Vyas, T. D., Vyas, J. M., Goldberg, M. B., Luban, J., Li, J. Z., Barczak, A. K., Lemieux, J. E.
10.1101/2022.03.02.22271731 — Posted: 2022-03-03
Evidence of co-infection during Delta and Omicron variants of concern co-circulation, weeks 49-2021 to 02-2022, France
COMBES, P., Bisseux, M., Bal, A., Marin, P., Archimbaud, C., Brebion, A., Chabrolles, H., Regagnon, C., Lafolie, J., Destras, G., Simon, B., josset, l., Henquell, C., MIRAND, A.
10.1101/2022.03.02.22271694 — Posted: 2022-03-03
A predictive model for hospitalization and survival to COVID-19 in a retrospective population-based study
Cisterna-Garcia, A., Guillen-Teruel, A., Caracena, M., Perez, E., Jimenez, F., Francisco-Verdu, F. J., Reina, G., Gonzalez-Billalabeitia, E., Palma, J. T., Sanchez-Ferrer, A., Botia, J. A.
10.1101/2022.03.02.22271552 — Posted: 2022-03-03
Optimal vaccination with time-varying based on immunity barrier in Hunan Province, China
Guo, X., Liu, Z., Yang, S., Zhao, Z., Guo, Y., Abudurusuli, G., Rui, J., Wang, Y., Zhao, S., Zeng, G., Hu, S., Luo, K., Chen, T.
10.1101/2022.03.02.22271610 — Posted: 2022-03-03
Amplification of Olfactory Signals by Anoctamin 9 is Essential for Mammalian Olfaction: a Risk Factor for the Covid-19-associated Anosmia
Kim, H., Kim, H., Nguyen, L. T., Ha, T., Lim, S., Kim, K., Kim, S. H., Han, K., Hyeon, S. J., Ryu, H., Park, Y. S., Kim, S. H., Kim, I.-B., Hong, G.-S., Lee, S. E., Choi, Y., Cohen, L. B., Oh, U.
10.1101/2022.03.02.482745 — Posted: 2022-03-03

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).